CollPlant CEO Yehiel Tal to Moderate ISBF's virtual event on Biofabrication of Microphysiological Systems for Drug Discovery and Screening

REHOVOT, Israel, April 25, 2022 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, today announced that CEO Yehiel Tal will moderate the International Society for Biofabrication's (ISBF) virtual event on May 2nd. Mr. Tal also serves as a board member of ISBF.

The event will be hosted by the ISBF's Industry Relations Committee and feature experts in the field from academia and industry: Dr. Daniel Levner, co-founder and CTO of Emulate, Dr. Ben Maoz from Tel Aviv University, Dr. Lutz Kloke, founder and CSO of Cellbricks and Dr. Jeroen Eyckmans from Boston University. The Q&A session will be moderated by Ms. Katie Weimer, VP Regenerative Medicine at 3D systems and a member of the ISBF's Industry Relations Committee.

Event title: Biofabrication of Microphysiological Systems for Drug Discovery and Screening - Future Outlook
Date: Monday, May 2, 2022
Time: 10:00 AM EST / 4:00 PM CET / 11:00 PM JST
Location: Virtual event
Registration link

The Industry Relations Committee of ISBF is serving as a mediator of academia-industry and industry-industry to promote and stimulate collaboration; developing mechanisms to facilitate translation of laboratory discoveries into manufactured products; and representing the industry in all Biofabrication aspects including roadmap, technologies, cell biology, large scale manufacturing, regulation, and commercialization.

For more details and to register, please visit 

About the International Society for Biofabrication

From basic science to medical applications, the biofabrication community convened at the International Conference on Biofabrication (Biofabrication 2019). The field of biofabrication is dedicated to researching and integrating technologies such as bio-printing, bio-plotting, and bio-assembly into applications such as engineered tissue systems and regenerative medicine. The International Society for Biofabrication's (ISBF) core purpose is to foster scientific and technological innovation and excellence for the benefit of humanity. ISBF promotes the interaction between and convergence in the different disciplines of the field of Biofabrication, as well as between basic research and applied practice. Further, the Society aims to promote the cooperation with other scientific organizations and communities.

About CollPlant

CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine.

At the beginning of 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. Later in 2021, CollPlant entered a strategic co-development agreement with 3D Systems for a 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures in combination with an implant.

For more information about CollPlant, visit

Safe Harbor Statements

This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its ability to continue as a going concern, and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the impact of the COVID-19 pandemic; the Company's expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on its rhCollagen based BioInk and products for medical aesthetics; the Company's ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based BioInk and medical aesthetics products including but not limited to acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products in 3D Bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations; the Company's reliance on third parties to conduct some or all aspects of its product manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates; projected capital expenditures and liquidity; changes in the Company's strategy; and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant is contained under the heading "Risk Factors" included in CollPlant's most recent annual report on Form 20-F filed with the SEC, and in other filings that CollPlant has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant's current views with respect to future events, and CollPlant does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. 

Contact at CollPlant:

Eran Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600

Photo -

Cision View original content to download multimedia:

SOURCE CollPlant